How should hyperglycemia with a blood glucose of 238 mg/dL be managed in the emergency department?

Management of Hyperglycemia of 238 mg/dL in the Emergency Department

For a blood glucose of 238 mg/dL in the emergency department, initiate subcutaneous rapid-acting insulin (insulin aspart) every 2 hours until glucose falls below 200 mg/dL, targeting a glucose level between 140-180 mg/dL for most patients. 1

Initial Assessment and Risk Stratification

First, determine if this represents a hyperglycemic emergency or uncomplicated hyperglycemia:

• Rule out DKA/HHS: Check for symptoms of severe dehydration, altered mental status, Kussmaul respirations, or fruity breath odor. If present, obtain serum osmolality, ketones, and electrolytes 2
• Assess clinical stability: A glucose of 238 mg/dL without signs of hyperglycemic crisis represents uncomplicated hyperglycemia that can be managed with subcutaneous insulin

Treatment Protocol

Subcutaneous Insulin Approach

Administer rapid-acting insulin aspart every 2 hours while the patient remains in the ED until blood glucose drops below 200 mg/dL 3, 1. This approach has been validated in randomized trials showing:

• Mean glucose reduction from 333 mg/dL to 158 mg/dL at ED discharge
• Low hypoglycemia risk (7.4% with glucose <70 mg/dL)
• Reduced hospital length of stay (3.8 vs 5.3 days) 3

Dosing strategy: Use a weight-based or fixed-dose protocol depending on your institution's guidelines. Studies have successfully used protocols with 2-hour monitoring intervals without prolonging ED length of stay 1.

Target Glucose Range

Aim for 140-180 mg/dL for most general medicine and surgery patients 2. The ADA and AACE consensus guidelines specifically recommend:

• Pre-meal targets: <140 mg/dL
• Random glucose targets: <180 mg/dL
• Acceptable range up to 200 mg/dL in patients with severe comorbidities or limited monitoring capability 2

Critical Monitoring Points

Check point-of-care glucose every 2 hours during active treatment in the ED 3, 1. This frequent monitoring is essential to:

• Titrate insulin doses appropriately
• Detect hypoglycemia early (glucose <70 mg/dL)
• Determine when target range is achieved

Monitor potassium levels if initiating insulin therapy, as insulin drives potassium intracellularly and hypokalaemia occurs in approximately 50% of patients during hyperglycemia treatment 2.

Transition Planning

If Admitting to Hospital

If the patient requires admission, initiate basal insulin (detemir or glargine) in the ED before transfer 1. This approach achieves:

• Lower admission glucose (184 vs 224 mg/dL)
• Better inpatient glycemic control (mean 163 vs 202 mg/dL)
• No increase in hypoglycemia risk 1

Avoid sliding scale insulin alone for admitted patients with known diabetes, as it is associated with worse glycemic control and is discouraged by clinical guidelines 2. Instead, transition to basal-bolus regimen.

If Discharging Home

For patients being discharged:

• Ensure glucose is trending toward target (<200 mg/dL)
• Arrange follow-up within 12-72 hours 4
• Provide diabetes self-management education
• Adjust or initiate outpatient diabetes medications 4

Common Pitfalls to Avoid

Do not use sliding scale insulin as monotherapy in patients with established diabetes—this reactive approach leads to persistent hyperglycemia and is condemned in guidelines 2. The evidence consistently shows basal-bolus approaches achieve superior glycemic control 2.

Do not delay insulin treatment waiting for admission or endocrine consultation. Studies demonstrate that 100% of protocol-driven patients received insulin versus only 35% of usual care patients, with significantly better outcomes 3.

Do not target aggressive glucose normalization (<100 mg/dL), as this increases hypoglycemia risk without additional benefit and may worsen outcomes 2.

Special Considerations

For patients at high risk of hypoglycemia (age ≥65 years, BMI ≤27 kg/m², chronic kidney disease, history of hypoglycemia), consider real-time CGM with confirmatory point-of-care testing if available, though this is a conditional recommendation for resource-equipped settings 5.

Standardized protocols improve outcomes: Implementation of ED-specific insulin protocols reduces average admission glucose by 65.8 mg/dL and decreases the percentage of patients admitted with glucose >250 mg/dL by 24.8% without increasing hypoglycemia, ED length of stay, or mortality 6.